Edition:
United States

Corcept Therapeutics Inc (CORT.OQ)

CORT.OQ on NASDAQ Stock Exchange Capital Market

16.37USD
2:24pm EDT
Change (% chg)

$-0.04 (-0.24%)
Prev Close
$16.41
Open
$16.38
Day's High
$16.57
Day's Low
$16.04
Volume
136,396
Avg. Vol
420,461
52-wk High
$25.92
52-wk Low
$11.22

Chart for

About

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive... (more)

Overall

Beta: 1.85
Market Cap(Mil.): $1,875.45
Shares Outstanding(Mil.): 115.24
Dividend: --
Yield (%): --

Financials

  CORT.OQ Industry Sector
P/E (TTM): 11.91 29.56 34.04
EPS (TTM): 1.38 -- --
ROI: 132.49 13.58 13.11
ROE: 132.49 15.39 15.11

BRIEF-Corcept Therapeutics Reports Qtrly Revenue $57.7 Million

* CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 08 2018

BRIEF-Corcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals For Infringement Of Korlym Patents

* CORCEPT THERAPEUTICS FILES LAWSUIT AGAINST TEVA PHARMACEUTICALS FOR INFRINGEMENT OF KORLYM PATENTS

Mar 15 2018

BRIEF-Corcept Therapeutics Q4 GAAP Earnings Per Share $0.77

* CORCEPT THERAPEUTICS ANNOUNCES 2017 FINANCIAL RESULTS AND POSITIVE INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL

Feb 22 2018

BRIEF-Corcept Therapeutics Q4 GAAP Earnings Per Share $0.77

* CORCEPT THERAPEUTICS ANNOUNCES 2017 FINANCIAL RESULTS AND POSITIVE INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL

Feb 22 2018

BRIEF-Corcept Therapeutics Receives Letter on saying Teva Pharmaceuticals USA Submitted An Abbreviated New Drug Application

* CORCEPT THERAPEUTICS - RECEIVED PARAGRAPH IV NOTICE LETTER ADVISING THAT TEVA PHARMACEUTICALS USA SUBMITTED AN ABBREVIATED NEW DRUG APPLICATION TO FDA

Feb 05 2018

BRIEF-Corcept Therapeutics, Dohmen Entered Into Settlement Agreement And Mutual Release Of Any And All Claims That May Have Existed Between Parties

* CORCEPT THERAPEUTICS - CO, DOHMEN ENTERED INTO SETTLEMENT AGREEMENT AND MUTUAL RELEASE OF ANY AND ALL CLAIMS THAT MAY HAVE EXISTED BETWEEN PARTIES

Jan 17 2018

Competitors

Earnings vs. Estimates